NovoCure (NVCR) Revenue (2014 - 2026)

NovoCure has disclosed Revenue across 13 years of filings, most recently posting $174.1 million for Q1 2026.

• Revenue for Q1 2026 came in at $174.1 million, up 12.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $674.4 million (up 8.48% YoY), and the FY2025 annual result was $655.4 million, up 8.28% from the prior year.
• Revenue came in at $174.1 million for Q1 2026 at NovoCure, roughly flat from $174.4 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $174.4 million in Q4 2025 to a low of $122.2 million in Q1 2023.
• The 5-year median for Revenue is $140.9 million (2022), against an average of $146.0 million.
• Across the five-year window, Revenue fell 11.17% in 2023 and gained 21.81% in 2024, its largest moves.
• NovoCure's Revenue stood at $128.4 million in 2022, then advanced by 4.17% to $133.8 million in 2023, then rose by 20.54% to $161.3 million in 2024, then grew by 8.11% to $174.4 million in 2025, then fell by 0.17% to $174.1 million in 2026.
• The last three Revenue figures came in at $174.1 million (Q1 2026), $174.4 million (Q4 2025), and $167.2 million (Q3 2025), per Business Quant data.